Hemostatic radiotherapy for inoperable gastric cancer: a pilot study

• Published in: British journal of radiology Vol. 93; no. 1111; p. 20190958
• Main Authors: Tanaka, Osamu, Sugiyama, Akihiko, Omatsu, Tatsushi, Tawada, Masahiro, Makita, Chiyoko, Matsuo, Masayuki
• Format: Journal Article
• Language: English
• Published: England The British Institute of Radiology 01.07.2020
• Subjects: Aged; Aged, 80 and over; Disease-Free Survival; Female; Gastrointestinal Hemorrhage - radiotherapy; Hemostasis - physiology; Humans; Male; Middle Aged; Patient Care Planning; Pilot Projects; Prospective Studies; Radiotherapy Dosage; Re-Irradiation - statistics & numerical data; Recurrence; Stomach Neoplasms - radiotherapy; Treatment Outcome
• ISSN: 0007-1285; 1748-880X
• DOI: 10.1259/bjr.20190958

Standard treatment for progressive gastric cancer with bleeding includes hemostatic radiotherapy (RT); however, the only prospective study using a fixed dose with fractions during hemostatic RT did not introduce re-irradiation. Therefore, we determined the utility of RT including re-irradiation for gastric cancer. In this study, 31 patients with gastric cancer and bleeding were treated with an initial dose of 20 Gy/5 fractions for the whole stomach and a salvage dose of 15 Gy/5 fractions for the partial stomach. Patients achieving hemostasis, defined as a stable hemoglobin level within 30 days following irradiation, were considered responders, whereas those with no cessation of bleeding and those with re-bleeding within 30 days of irradiation were considered non-responders. We evaluated response rate, disease-free survival, overall survival (OS), re-irradiation, and adverse events (AEs). The response rate of initial RT was 80% (25/31). 6 of the 25 patients underwent re-irradiation, and all 6 were responders (100%). The median OS was significantly different among the entire cohort and one-time irradiation and re-irradiation groups (91, 76, and 112 days, respectively). No AEs of grade ≥3 were observed. Initial low-dose RT followed by reirradiation was effective in reducing AEs and did not cause any further AEs. Hemostatic RT was an effective approach with low toxicity, and re-irradiation was effective and tolerable, with no patients developing severe AEs. Further, randomized controlled studies are warranted to determine the ideal dose and number of fractions for initial RT in patients with gastric cancer and bleeding. In this prospective study on hemostatic radiotherapy for gastric cancer, the response rate was 80% using a fixed dose of 20 Gy/5 fractions and the salvage dose of 15 Gy for re-bleeding was effective. Future comparative studies should include other doses with 20 Gy as a control.